Literature DB >> 16173962

Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001.

Merete Stubkjaer Christensen1, Mats Heyman, Merja Möttönen, Bernward Zeller, Gudmundur Jonmundsson, Henrik Hasle.   

Abstract

Despite continuously more successful treatment of childhood acute lymphoblastic leukaemia (ALL), 2-5% of children still die of other causes than relapse. The Nordic Society of Paediatric Haematology and Oncology-ALL92 protocol included 1652 patients < or =15 years of age with precursor B- and T-cell ALL diagnosed between 1992 and 2001. Induction deaths and deaths in first complete remission (CR1) were included in the study. A total of 56 deaths (3%) were identified: 19 died during induction (1%) and 37 in CR1 (2%). Infection was the major cause of death in 38 cases. Five patients died of early death before initiation of cytotoxic therapy. Five patients died because of toxicity of inner organs and one of accidental procedure failures. Seven patients died of complications following allogenic haematopoietic stem cell transplantation (HSCT) in CR1. Girls were at higher risk of treatment-related death (TRD) [relative risk (RR) = 2.2; 95% confidence interval (CI(95%)): 1.2-4.0, P < 0.01], mostly because of infections. Risk of TRD was also higher in children with Down syndrome (RR = 4.5; CI(95%): 2.0-10.2, P < 0.00). In conclusion, 3% of children with ALL died of TRD, with bacterial infections as the most common cause of death. Girls and Down syndrome patients had a higher risk of TRD. Infections still remain a major challenge in childhood ALL.

Entities:  

Mesh:

Year:  2005        PMID: 16173962     DOI: 10.1111/j.1365-2141.2005.05736.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Infection-related complications during treatment for childhood acute lymphoblastic leukemia.

Authors:  H Inaba; D Pei; J Wolf; S C Howard; R T Hayden; M Go; O Varechtchouk; T Hahn; J Buaboonnam; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C Cheng; W E Evans; M V Relling; C-H Pui
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

2.  Milestones in the curability of pediatric cancers.

Authors:  Melissa M Hudson; Michael P Link; Joseph V Simone
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

3.  Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

Authors:  Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-02-13       Impact factor: 3.167

4.  Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data.

Authors:  Brian T Fisher; Tracey Harris; Kari Torp; Alix E Seif; Ami Shah; Yuan-Shung V Huang; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana Walker; Yimei Li; Richard Aplenc
Journal:  Med Care       Date:  2014-01       Impact factor: 2.983

5.  FIBCD1 ameliorates weight loss in chemotherapy-induced murine mucositis.

Authors:  Maria C E Andersen; Malene W Johansen; Thomas Nissen; Anders B Nexoe; Gunvor I Madsen; Grith L Sorensen; Uffe Holmskov; Anders Schlosser; Jesper B Moeller; Steffen Husby; Mathias Rathe
Journal:  Support Care Cancer       Date:  2020-09-12       Impact factor: 3.603

6.  Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.

Authors:  Emma Crutchlow; Yohannie Miombe; Tom Latham
Journal:  Malawi Med J       Date:  2008-12       Impact factor: 0.875

Review 7.  Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.

Authors:  Niki Rensen; Reinoud Jbj Gemke; Elvira C van Dalen; Joost Rotteveel; Gertjan Jl Kaspers
Journal:  Cochrane Database Syst Rev       Date:  2017-11-06

8.  Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia.

Authors:  Alix E Seif; Brian T Fisher; Yimei Li; Kari Torp; Douglas P Rheam; Yuan-Shung V Huang; Tracey Harris; Ami Shah; Matthew Hall; Evan S Fieldston; Marko Kavcic; Marijana Vujkovic; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana M Walker; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2013-11-19       Impact factor: 3.167

9.  Suppressed neutrophil function in children with acute lymphoblastic leukemia.

Authors:  Fumiko Tanaka; Hiroaki Goto; Tomoko Yokosuka; Masakatsu Yanagimachi; Ryosuke Kajiwara; Takuya Naruto; Shigeru Nishimaki; Shumpei Yokota
Journal:  Int J Hematol       Date:  2009-09-02       Impact factor: 2.490

10.  Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.

Authors:  Trausti Oskarsson; Stefan Söderhäll; Johan Arvidson; Erik Forestier; Scott Montgomery; Matteo Bottai; Birgitte Lausen; Niels Carlsen; Marit Hellebostad; Päivi Lähteenmäki; Ulla M Saarinen-Pihkala; Ólafur G Jónsson; Mats Heyman
Journal:  Haematologica       Date:  2015-10-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.